APA (7th ed.) Citation

EK, M., A, N., HM, L., B, v. d. H., S, Z., KC, W., . . . P, S. (2024). Bortezomib before and after high-dose therapy in transplant-eligible patients with newly diagnosed multiple myeloma: Long-term overall survival after more than 10 years of follow-up from the phase III HOVON-65/GMMG-HD4 trial. HemaSphere, 8(11), e70052. https://doi.org/10.1002/hem3.70052

Chicago Style (17th ed.) Citation

EK, Mai, et al. "Bortezomib Before and After High-dose Therapy in Transplant-eligible Patients with Newly Diagnosed Multiple Myeloma: Long-term Overall Survival After More than 10 Years of Follow-up from the Phase III HOVON-65/GMMG-HD4 Trial." HemaSphere 8, no. 11 (2024): e70052. https://doi.org/10.1002/hem3.70052.

MLA (9th ed.) Citation

EK, Mai, et al. "Bortezomib Before and After High-dose Therapy in Transplant-eligible Patients with Newly Diagnosed Multiple Myeloma: Long-term Overall Survival After More than 10 Years of Follow-up from the Phase III HOVON-65/GMMG-HD4 Trial." HemaSphere, vol. 8, no. 11, 2024, p. e70052, https://doi.org/10.1002/hem3.70052.